Recent Publications
Remodeling of the tumor microenvironment via disrupting Blimp1+ effector regulatory T-cells augments response to anti-PD-1 blockade.
Dixon ML,Luo L, Ghosh S, Grimes JM, LeavenworthJD, LeavenworthJW.
Mol Cancer (Impact factor: 27.4), 2021. doi: 10.1186/s12943-021-01450-3 Accepted
RNF2 ablation reprograms the tumor-immune microenvironment and stimulates durable NK and CD4+T-cell-dependent antitumor immunity.
Zhuo Z*,#, Luo L*, Xing C, Chen Y, Xu P, Li M, Zeng L, Li C, Ghosh S, Manna DD, Townes T, Britt WJ, Wajapeyee N, Sleckman BP, Chong Z, LeavenworthJW#, Yang ES#.
Nat Cancer. 2021; 2, 1018-1038. https://doi.org/10.1038/s43018-021-00263-z (*co-first author; #co-senior author).
>> News & Views, Nat Cancer. 2021. A PRC1-RNF2 knockout punch for cancer
Lineage Reprogramming of effector regulatory T cells in cancer.
Dixon ML, LeavenworthJD, LeavenworthJW.
Front Immunol. 2021 Jul 28;12:717421. doi: 10.3389/fimmu.2021.717421. PMID: 34394124
Immune activity and response differences of oncolytic viral therapy in recurrent glioblastoma: gene expression analyses of a Phase IB study.
Miller KE,Cassady KA, Roth JC, Clements J, Schieffer KM, Leraas K, Miller AR, Prasad N, LeavenworthJW, Aban IB, Whitley RJ, Gillespie GY, Mardis ER and Markert JM.
Clin cancer Res. 2021 Accepted
Dysregulated follicular regulatory T cells and antibody responses exacerbate EAE.
Luo L, Hu X, Dixon ML, Pope BJ, LeavenworthJD, Raman C, Meador WR, LeavenworthJW.
J Neuroinflammation. 2021 Jan 19;18(1):27. PMID: 33468194
